Glyoxal (40% w/w in water)
Based on 1 Customer Validation
Glyoxal (40% w/w in water) is an α-oxoaldehyde that inhibits Aldose Reductase, Glutathione Reductase, and NADPH synthase. Glyoxal (40% w/w in water) exhibits cytotoxicity, triggers oxidative stress, induces ROS accumulation, lipid peroxidation, mitochondrial membrane potential collapse, DNA damage, apoptosis, and massive production of advanced glycation end products (AGEs). Glyoxal (40% w/w in water) depletes glutathione and activates MAPK phosphorylation. It has lower toxicity as a fixative than paraformaldehyde (PFA) and serves as a precursor for the synthesis of oxalates and dietary carcinogens. Glyoxal (40% w/w in water) is suitable for research related to calcium oxalate kidney stones, diabetes, atherosclerosis, cardiovascular diseases, retinopathy, and cataracts.
For research use only. We do not sell to patients.
- CAS No.: 107-22-2
- Formula: C2H2O2
- Molecular Weight:58.04
-
Storage:
Store at room temperature, keep dry and cool.
In solvent -80°C, 1 year , -20°C, 6 months
Biological Activity
Description
|
p38 MAPK |
JNK |
ERK |
In Vitro
Glyoxal (40% w/w in water) drives NAD+-dependent glyoxylate production in human liver tissue homogenates and generates oxalate in HepG2 hepatocellular carcinoma cells[1].
Glyoxal (40% w/w in water) induces concentration- and time-dependent cytotoxicity, lipid peroxidation, and inhibition of its own metabolism in isolated rat hepatocytes[2].
Glyoxal (1-5 mM; 25-165 min) (40% w/w in water) induces concentration- and time-dependent ROS production in isolated rat hepatocytes[2].
Glyoxal (0.5-10 mM; 25-135 min) (40% w/w in water) induces concentration-dependent GSH depletion and GSSG production in isolated rat hepatocytes[2].
Glyoxal (0.5-5 mM) (40% w/w in water) inhibits cytosolic glutathione reductase activity in rat hepatocyte fractions in a concentration- and time-dependent manner in vitro, with an IC50 of 3 mM[2].
Glyoxal (40% w/w in water)-induced cellular injury, inflammation and oxidative stress can be alleviated by Resveratrol (HY-16561), Luteolin (HY-N0162), morin and Mangiferin (HY-N0290) as well as Clostridium butyricum through regulating immune signaling pathways or cellular detoxification systems, respectively[4].\n
Glyoxal (0.12 mM; 8 days) (40% w/w in water) reduces glutathione levels and mitochondrial membrane potential, and increases the proportion of oxidized Trx1 in human aortic endothelial cells[5].
Glyoxal (5-8 mM) (40% w/w in water) induces concentration- and time-dependent collapse of mitochondrial membrane potential in isolated rat hepatocytes[2].
Glyoxal (1-10 mM; 4-12 h) (40% w/w in water) induces cytotoxicity by reducing mitochondrial activity in bovine pulmonary artery endothelial cells[6].
Glyoxal (40% w/w in water) exhibits faster penetration efficiency through the cell membrane of COS-7 cells compared with PFA (HY-DY3003). It can rapidly terminate cellular endocytosis, and shows superior performance in terms of cell morphology, cytoplasmic protein cross-linking and nucleic acid fixation. It reduces the half amount of unfixed proteins and maintains the detection signal of RNA fluorescence in situ hybridization[3].
Glyoxal (40% w/w in water) enhances the fluorescence intensity of STED staining and multiple synaptic/skeletal proteins in rat hippocampal neurons compared with PFA; only the staining signals of LC3B and vimentin are weaker than those with PFA. It is suitable for a variety of cell and tissue samples including cardiac, neural and olfactory epithelial samples. When used for fixation of mouse olfactory epithelium and olfactory bulb, it also yields a higher signal-to-noise ratio for immunostaining[3].
Glyoxal (40% w/w in water) can be sequestered and bound by aspartame to reduce its free content and block in vitro glycation reactions. Additionally, the glyoxal-induced glycation of human serum albumin can be inhibited by Naringin (HY-N0153), Naringenin (HY-N0100), and Quercetin (HY-18085) via competitive occupation of the binding sites on lysine and arginine residues of the protein[4].
Glyoxal (40% w/w in water) can be captured and bound by Gallic acid (HY-N0523), Quercetin, glycine, serine, κ-carrageenan, alginic acid and pectin, thereby reducing the content of free Glyoxal in pH 7.0 phosphate buffer, pH 7.4 phosphate buffer, and lysine-glucose model system, respectively[4].
Glyoxal (GX) (50-200 μM; 8 days) (40% w/w in water) reduces the viability of wild-type and FANC pathway-deficient human aortic endothelial cells, with LD90 values of 0.12 mM and 0.125 mM, respectively[5].
Glyoxal (0.12 mM) (40% w/w in water) activates the mitogen-activated protein kinase pathway in human aortic endothelial cells, increasing the phosphorylation levels of ERK, JNK and p38 to 105%, 314% and 159% of those in the control group, respectively[5].
Glyoxal (1-5 mM; 12 h) (40% w/w in water) induces cytotoxicity in bovine pulmonary artery endothelial cells via membrane damage, with significant LDH release observed[6].
Glyoxal (1 mM; 6-24 h) (40% w/w in water) induces progressive loss of morphology in bovine pulmonary artery endothelial cells[6].
Glyoxal (1-10 mM; 4-12 h) (40% w/w in water) induces actin cytoskeleton rearrangement in bovine pulmonary artery endothelial cells; induces alterations in tight junctions of bovine pulmonary artery endothelial cells; dose-dependently induces the formation of advanced glycation end products (Amadori products) in bovine pulmonary artery endothelial cells; and almost completely inhibits in vitro angiogenesis of bovine pulmonary artery endothelial cells[6].
Glyoxal (1-10 mM; 6 h) (40% w/w in water) dose-dependently inhibits DNA synthesis and replication in bovine pulmonary artery endothelial cells[6].
Glyoxal (1-5 mM; 2-10 h) (40% w/w in water) induces barrier dysfunction in bovine pulmonary artery endothelial cell monolayers in a dose- and time-dependent manner[6].
Glyoxal (200-800 μM; 1-24 h) (40% w/w in water) induces dose- and time-dependent intracellular acidification, mitochondrial depolarization, morphological damage and apoptosis in E1A-NR3 retinal cells[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:wild-type and FANC pathway-deficient human aortic endothelial cells
-
Concentration:0, 50, 100, 150, 200 μM
-
Incubation Time:8 days
-
Result:Reduced the survival rate of wild-type and FANC pathway-deficient human aortic endothelial cells, with LD90 values of 0.12 mM and 0.125 mM, respectively.
-
Cell Line:human aortic endothelial cells (HAECs)
-
Concentration:0.12 mM (LD90)
-
Incubation Time:8 days
-
Result:Caused an upper shift of Trx1 bands on urea-PAGE, indicating altered redox state.
Increased the proportion of oxidized Trx1 from ~35% in untreated control cells to ~90% in treated cells, a statistically significant change.
-
Cell Line:bovine pulmonary artery endothelial cells (BPAECs)
-
Concentration:1, 5, 10 mM
-
Incubation Time:4 h, 6 h, 12 h
-
Result:Caused a significant, dose-dependent decrease in mitochondrial dehydrogenase activity compared to vehicle-treated controls.
-
Cell Line:bovine pulmonary artery endothelial cells (BPAECs)
-
Concentration:1 mM, 5 mM
-
Incubation Time:12 h
-
Result:Caused a significant increase in LDH release compared to vehicle-treated controls.
Induced a slightly lower significant increase in LDH release at 5 mM than at 1 mM.
-
Cell Line:bovine pulmonary artery endothelial cells (BPAECs)
-
Concentration:1, 5, 10 mM
-
Incubation Time:6 h
-
Result:Caused a significant, dose-dependent decline in [3H]-thymidine incorporation compared to controls.
Indicated reduced cellular DNA synthesis and replication in BPAECs.
-
Cell Line:bovine pulmonary artery endothelial cells (BPAECs)
-
Concentration:1 mM
-
Incubation Time:4 h
-
Result:Caused marked disappearance of the regular peripheral localization of ZO-1 tight junction protein, which was maintained in control untreated BPAECs.
-
Cell Line:bovine pulmonary artery endothelial cells (BPAECs)
-
Concentration:1, 5, 10 mM
-
Incubation Time:4 h
-
Result:Induced a dose-dependent increase in intracellular formation of Amadori Products (a type of advanced glycation end product) in BPAECs compared to controls.
Chemical Information
-
CAS No. 107-22-2
-
Appearance Liquid (Density: 1.14 g/cm3)
-
Molecular Weight 58.04
-
Formula C2H2O2
-
Color Colorless to light yellow
-
SMILES
O=CC=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature, keep dry and cool
In solvent -80°C 1 year -20°C 6 months
Solvent & Solubility
In Vitro:
DMSO : 200 mg/mL (3445.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (86.15 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (86.15 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (560 KB)
- English - EN (560 KB)
- Français - FR (560 KB)
- Deutsch - DE (560 KB)
- Norwegian - NO (560 KB)
- Español - ES (560 KB)
- Swedish - SV (560 KB)
- Italian - IT (560 KB)
- Korean - KR (560 KB)
- Portuguese - PT (560 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lange JN, et al. Glyoxal formation and its role in endogenous oxalate synthesis. Advances in urology. 2012;2012:819202. [Content Brief]
[2]. Shangari N, et al. The cytotoxic mechanism of glyoxal involves oxidative stress. Biochemical pharmacology. 2004 Oct 01;68(7):1433-42. [Content Brief]
[3]. Richter KN, et al. Glyoxal as an alternative fixative to formaldehyde in immunostaining and super-resolution microscopy. The EMBO journal. 2018 Jan 04;37(1):139-159. [Content Brief]
[4]. Zhang M, et al. Glyoxal in Foods: Formation, Metabolism, Health Hazards, and Its Control Strategies. Journal of agricultural and food chemistry. 2024 Feb 07;72(5):2434-2450. [Content Brief]
[5]. Xie MZ, et al. Glyoxal damages human aortic endothelial cells by perturbing the glutathione, mitochondrial membrane potential, and mitogen-activated protein kinase pathways. BMC cardiovascular disorders. 2021 Dec 18;21(1):603. [Content Brief]
[6]. Sliman SM, et al. Hyperglycemic oxoaldehyde, glyoxal, causes barrier dysfunction, cytoskeletal alterations, and inhibition of angiogenesis in vascular endothelial cells: aminoguanidine protection. Molecular and cellular biochemistry. 2010 Jan;333(1-2):9-26. [Content Brief]
[7]. Reber F, et al. Alteration of the intracellular pH and apoptosis induction in a retinal cell line by the AGE-inducing agent glyoxal. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2002 Dec;240(12):1022-32. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 17.2295 mL | 86.1475 mL | 172.2950 mL | 430.7374 mL |
| 5 mM | 3.4459 mL | 17.2295 mL | 34.4590 mL | 86.1475 mL | |
| 10 mM | 1.7229 mL | 8.6147 mL | 17.2295 mL | 43.0737 mL | |
| 15 mM | 1.1486 mL | 5.7432 mL | 11.4863 mL | 28.7158 mL | |
| 20 mM | 0.8615 mL | 4.3074 mL | 8.6147 mL | 21.5369 mL | |
| 25 mM | 0.6892 mL | 3.4459 mL | 6.8918 mL | 17.2295 mL | |
| 30 mM | 0.5743 mL | 2.8716 mL | 5.7432 mL | 14.3579 mL | |
| 40 mM | 0.4307 mL | 2.1537 mL | 4.3074 mL | 10.7684 mL | |
| 50 mM | 0.3446 mL | 1.7229 mL | 3.4459 mL | 8.6147 mL | |
| 60 mM | 0.2872 mL | 1.4358 mL | 2.8716 mL | 7.1790 mL | |
| 80 mM | 0.2154 mL | 1.0768 mL | 2.1537 mL | 5.3842 mL | |
| 100 mM | 0.1723 mL | 0.8615 mL | 1.7229 mL | 4.3074 mL |
Keywords
- Glyoxal (40% w/w in water)
- 107-22-2
- Aldose Reductase
- Glutathione Reductase (GR)
- p38 MAPK
- ERK
- JNK
- Reactive Oxygen Species (ROS)
- Apoptosis
- Drug Intermediate
- HeLa cells
- aldehyde dehydrogenase
- glutathione reductase
- glyoxalase system
- human aortic endothelial cells
- COS-7 fibroblast cell
- AtT20 cells
- bovine pulmonary artery endothelial cells
- HepG2 hepatoma cells
- aldehyde reductase
- Inhibitor
- inhibitor
- inhibit